Cowen Inc, a diversified financial services firm that provides sales, trading and prime brokerage services, announced on Tuesday that it has made two hires to its senior management team. Bobby Croswell has joined the firm’s outsourced trading group as Managing Director and Head of Business Development, whilst Dr. Yaron Werber has been appointed as a senior biotechnology analyst.
Croswell has a lot of experience in the finance industry. In his new role, he will be located in the firm’s Boston office. He will be responsible for expanding the outsourced trading business, both within the US and throughout the world.
With the addition of Croswell, Cowen’s outsourced trading team is comprised of 20 professionals. They are based in the US, London, Belfast and soon Hong Kong too. Most recently, Croswell was a partner and Managing Director of BTIG. He worked in the company’s outsourced trading division for close to 12 years.
Commenting on his new position, Croswell said: “I’ve built my reputation on a client-first mentality and am inspired by Cowen’s industry leading technology, global MiFID II capabilities, as well as Cowen’s outsourced model, which most closely represents the true buy-side experience.”
Ready to kick-off your Trading Game with Manchester United?Go to article >>
Dr. Yaron Werber
Werber will be joining Cowen’s equity research team in his new position, which will be effective from September 24, 2018. At Cowen, he will be based in New York and will report to Robert Fagin, Cowen’s Director of Research.
This is not Werber’s first time working for Cowen. In fact, between 2001 until 2004 he was Vice President and Senior Biotech Analyst at the company in New York. His most recent position was at Ovid Therapeutics Inc. (Ovid), a biopharmaceutical company. Here he held the position of Chief Business and Financial Officer.
He joined the company in 2015 following nearly 15 years spent as a highly-ranked biotechnology research analyst at Cowen and then Citi Research between 2004 until 2015. Werber has also been a venture advisor for the Israel Biotech Fund since 2015.
Jeffrey Solomon, Cowen’s Chief Executive Officer, added: “We are thrilled to welcome Yaron back to equity research and back to Cowen, where he began his impressive career in biotech.
As a trained medical doctor, respected public company CFO and a proven sell-side analyst, Yaron is an outstanding addition to Cowen’s leading healthcare and biotech research team, and will be part of a highly collaborative group of industry experts dedicated to helping us deliver on our number one priority for clients: outperformance.”